Charles River Laboratories International, Inc. (CRL)

Market Cap	9.07B +21.5%
Revenue (ttm)	4.02B -0.9%
Net Income	-144.34M
EPS	-2.91
Shares Out	49.34M
PE Ratio	n/a
Forward PE	16.64
Dividend	n/a
Ex-Dividend Date	n/a

Volume	745,279
Open	180.31
Previous Close	176.94
Day's Range	179.07 - 185.61
52-Week Range	99.80 - 228.88
Beta	1.62
Analysts	Buy
Price Target	198.27 (+7.83%)
Earnings Date	May 7, 2026

About CRL

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, ins...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 23, 2000
• Employees: 19,700
• Stock Exchange: NYSE
• Ticker Symbol: CRL
• Website: https://www.criver.com

Analyst Summary

According to 12 analysts, the average rating for CRL stock is "Buy." The 12-month stock price target is $198.27, which is an increase of 7.83% from the latest price.

Price Target

$198.27

(7.83% upside)

Analyst Consensus: Buy